Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.

Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts